Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA4 | P22748 | 2/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | TNKS | O95271 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15476799 | 1.00 | CA1 (0.62) | CA1CA2CA4NFKB1HDAC3 | |
| SCHEMBL28499 | 1.00 | CA1 (0.62) | CA1CA2CA4NFKB1HDAC3 | |
| SCHEMBL13860588 | 0.94 | CA1 (0.56) | CA1CA2CA4NFKB1HDAC3 | |
| SCHEMBL8902281 | 0.87 | ALDH1A1 (0.62) | CA1CA2CA4NFKB1HDAC8 | |
| SCHEMBL70202 | 0.87 | ALDH1A1 (0.62) | CA1CA2CA4NFKB1HDAC8 | |
| SCHEMBL70201 | 0.87 | ALDH1A1 (0.62) | CA1CA2CA4NFKB1HDAC8 | |
| SCHEMBL69543 | 0.84 | NFKB1 (0.75) | CA1CA2CA4NFKB1HDAC3 | |
| SCHEMBL31197561 | 0.84 | NFKB1 (0.75) | CA1CA2CA4NFKB1HDAC3 | |
| SCHEMBL459291 | 0.84 | NFKB1 (0.75) | CA1CA2CA4NFKB1HDAC3 | |
| SCHEMBL15476829 | 0.84 | ALDH1A1 (0.48) | CA1CA2CA4NFKB1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240123074-A1 | MINIMALLY TOXIC PRODRUGS | COBIORES NV (BE) | 2024-04-18 | — | — | US | claimed |
| EP-1526584-B1 | Method of forming electroluminescent semiconducting nanocrystal patterned layer for an organic-inorganic hybrid electroluminescent devices, and organic-inorganic hybrid electroluminescent device using the same. | SAMSUNG ELECTRONICS CO LTD (KR) | 2017-06-14 | — | — | EP | claimed |
| US-8993494-B2 | Compositions comprising reverse micelles and methods for their use | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-03-31 | — | — | US | claimed |
| US-8911883-B2 | Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and method for forming semiconductor nanocrystal pattern using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-12-16 | — | — | US | claimed |
| US-8758864-B2 | Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and method for forming semiconductor nanocrystal pattern using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-06-24 | — | — | US | claimed |
| US-20130011635-A1 | PHOTOSENSITIVE SEMICONDUCTOR NANOCRYSTALS, PHOTOSENSITIVE COMPOSITION COMPRISING SEMICONDUCTOR NANOCRYSTALS AND METHOD FOR FORMING SEMICONDUCTOR NANOCRYSTAL PATTERN USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2013-01-10 | — | — | US | claimed |
| WO-2012073385-A1 | COMPOSITIONS COMPRISING REVERSE MICELLES AND METHODS FOR THEIR USE | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2012-06-07 | — | — | WO | claimed |
| US-20120141681-A1 | COMPOSITIONS COMPRISING REVERSE MICELLES AND METHODS FOR THEIR USE | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2012-06-07 | — | — | US | claimed |
| US-8034787-B2 | Enzyme-cleavable prodrug compounds | MEDAREX, INC. (US) | 2011-10-11 | — | — | US | claimed |
| WO-2011113013-A2 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| EP-1294405-A2 | PRODRUG COMPOUNDS CLEAVABLE BY THIMET OLIGOPEPTIDASE | CORIXA CORPORATION (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2002100353-A2 | CD10-ACTIVATED PRODRUG COMPOUNDS | MEDAREX, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| US-20020142955-A1 | Enzyme-cleavable prodrug compounds | E. R. SQUIBB & SONS, L.L.C. | 2002-10-03 | — | — | US | claimed |
| WO-2002000263-A2 | TRIPEPTIDE PRODRUG COMPOUNDS | MEDAREX, INC. (US) | 2002-01-03 | — | — | WO | claimed |
| WO-2001095943-A2 | PRODRUG COMPOUNDS WITH AN OLIGOPEPTIDE HAVING AN ISOLEUCINE RESIDUE | MEDAREX, INC. (US) | 2001-12-20 | — | — | WO | claimed |
| WO-2001095945-A2 | PRODRUG COMPOUNDS CLEAVABLE BY THIMET OLIGOPEPTIDASE | MEDAREX, INC. (US) | 2001-12-20 | — | — | WO | claimed |
| US-6143379-A | Polymer laminates having increased hiding power | CLARIANT GMBH (DE) | 2000-11-07 | — | — | US | claimed |
| EP-0039472-B1 | RADIATION-CROSSLINKABLE POLYESTERS AND POLYESTERETHERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-15 | — | — | EP | claimed |
| EP-0039472-A1 | Radiation-crosslinkable polyesters and polyesterethers | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-11-11 | — | — | EP | claimed |
| US-4284710-A | FROM DIEPOXIDE AND AROMATIC UNSATURATED DICARBOXYLIC ACID OR HYDROXY ACID | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-08-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123074-A1 | MINIMALLY TOXIC PRODRUGS | ALG8, ALG1, LNPEP | CA1 901/4885CA2 1548/4885CA4 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.